Insiders Buying Freshpet And 2 Other Stocks

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Funko

  • The Trade: Funko, Inc. FNKO 10% owner Chan Kenneth Hsiang-Tze acquired a total of 35,699 shares an average price of $6.11. To acquire these shares, it cost around $218,232.
  • What’s Happening: Funko reported a second-quarter earnings miss and issued weak guidance.
  • What Funko Does: Funko Inc is an US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team.

Freshpet

  • The Trade: Freshpet, Inc. FRPT Director Walter George acquired a total of 1,000 shares at an average price of $73.53. To acquire these shares, it cost around $73,525.
  • What’s Happening: Freshpet said it has entered into a cooperation agreement with JANA Partners, one of the Company’s largest shareholders.
  • What Freshpet Does: Freshpet Inc manufactures and markets natural fresh meals and treats for dogs and cats.

Don’t forget to check out our premarket coverage here

Aclaris Therapeutics

  • The Trade: Aclaris Therapeutics, Inc. ACRS Chief Business Officer James Loerop bought a total of 14,705 shares at an average price of $6.80. To acquire these shares, it cost around $99,959.
  • What’s Happening: Net loss was $29.6 million for the second quarter versus $20.5 million for the year-ago quarter.
  • What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases.

Check This Out: Top 3 Utilities Stocks That Could Blast Off In Q3

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsSmall CapInsider TradesPre-Market OutlookMarketsTrading IdeasInsiders Buying
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...